Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652418 | 0.83 | L3MBTL1 (0.39) | L3MBTL1ADORA2AIKBKBIDO1AXL | |
| SCHEMBL22367851 | 0.79 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL2422417 | 0.76 | GRIN2D (0.36) | L3MBTL1ADORA2AAXL | |
| SCHEMBL2427240 | 0.76 | L3MBTL1 (0.35) | L3MBTL1AXL | |
| SCHEMBL21875495 | 0.74 | PTK2 (0.37) | — | |
| SCHEMBL12618886 | 0.72 | L3MBTL1 (0.37) | L3MBTL1ADORA2AIKBKBIDO1 | |
| SCHEMBL16848682 | 0.72 | L3MBTL1 (0.38) | L3MBTL1ADORA2AIKBKBIDO1HRH4 | |
| SCHEMBL19456714 | 0.72 | L3MBTL1 (0.38) | L3MBTL1ADORA2AIKBKBIDO1AXL | |
| SCHEMBL29196677 | 0.72 | CYP1A2 (0.33) | L3MBTL1IDO1 | |
| Hydrochloric Acid SCHEMBL16241469 | 0.71 | L3MBTL1 (0.37) | L3MBTL1ADORA2AIKBKBIDO1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022121914-A1 | OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121914-A1 | OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | L3MBTL1 3280/4885ADORA2A 3896/4885IKBKB 29/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | L3MBTL1 3280/4885ADORA2A 3896/4885IKBKB 29/4885 |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | L3MBTL1 3280/4885ADORA2A 3896/4885IKBKB 29/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | L3MBTL1 3833/4885ADORA2A 3783/4885IKBKB 32/4885 |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | L3MBTL1 3833/4885ADORA2A 3783/4885IKBKB 32/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | L3MBTL1 3280/4885ADORA2A 3896/4885IKBKB 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.